Prognosis of Peyronies Disease First and foremost, patients are reassured that the plaque is not a tumor and will not affect their lives negatively
FDAs May 2026 TB-500 assessment stated that it found no human data for products containing the defined TB-500 substances and found insufficient nonclinical evidence to support wound-healing effectiveness
Using cyanocobalamin needs careful thought about possible bad effects
Theoretical and community-reported concerns Broad tissue exposure ERR receptors are widely expressed across heart, brain, kidney, liver, adipose tissue, and gut, so systemic pan-ERR agonism is not tissue-selective
As physicians, our goal is to rely on safe, evidence-based treatments
I feel like such a better person all around thanks to the products